Clik here to view.
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in...
TOKYO & MUNICH & BASKING RIDGE, N.J. & NASHVILLE, Tenn. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute (Sarah Cannon) announced today...
View ArticleClik here to view.
U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for...
View ArticleClik here to view.
美国FDA核准武田ALUNBRIG® (brigatinib)用作一种罕见严重类型肺癌患者的一线治疗选择
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited) (TSE:4502/NYSE:TAK)今天宣布，美国食品药品管理局(FDA)核准ALUNBRIG...
View ArticleClik here to view.
希少な重篤肺がんと診断された患者に対するファーストライン治療としての武田薬品のALUNBRIG®（ブリガチニブ）を米国FDAが承認
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Terns Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
FOSTER CITY, Calif. & SHANGHAI Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat liver disease and cancer, today...
View ArticleClik here to view.
Qurient Announces U.S. FDA Clearance of IND Application for Q702, a Novel...
SEONGNAM-SI, Korea Qurient Co. Ltd. (KRX: 115180), a clinical stage biotech company in Korea, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new...
View ArticleClik here to view.
EdiGene and Immunochina Announce Research and Development Collaboration to...
BEIJING, China & CAMBRIDGE, Mass. EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, and...
View ArticleClik here to view.
Vaxxas Announces That MSD Exercises Option to Apply Novel Immune System...
BRISBANE, Australia Vaxxas, a biotechnology company commercializing a novel vaccination platform, today announced that MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ USA, has exercised...
View ArticleClik here to view.
New data show first-line triplet regimen of pembrolizumab, Herzuma®...
INCHEON, South Korea Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma® (biosimilar trastuzumab) and...
View ArticleClik here to view.
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2...
TOKYO & BASKING RIDGE, N.J. & MUNICH Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab...
View ArticleClik here to view.
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2...
TOKYO & BASKING RIDGE, N.J. & MUNICH Results from the ongoing phase 2 DESTINY-Lung01 trial showed Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU®...
View ArticleClik here to view.
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in...
TOKYO & BASKING RIDGE, N.J. & MUNICH Detailed results from the positive pivotal randomized, controlled phase 2 DESTINY-Gastric01 trial showed Daiichi Sankyo Company, Limited (hereafter,...
View ArticleClik here to view.
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration agreement with a subsidiary...
View ArticleClik here to view.
Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting...
DAEJEON, South Korea Alteogen Inc. (KOSDAQ:196170) has today presented at ASCO results from the First-in-Human (FIH), phase 1 study of ALT-P7, a HER2-targeting antibody-drug conjugate (ADC), in...
View ArticleClik here to view.
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral...
View ArticleClik here to view.
Fibralign Announces Strategic Partnership With Terumo
UNION CITY, Calif. Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced today that it has executed a long term distributor agreement with Terumo...
View ArticleClik here to view.
武田发布Pevonedistat联合阿扎胞苷治疗较高危MDS患者2期试验的有力数据
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited,...
View ArticleClik here to view.
武田薬品、高リスクMDS患者でpevonedistatとアザシチジンの併用療法を検討する第2相試験の有力なデータを発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Noxopharm Reports Veyonda’s Potential in Late-Stage Cancer at ASCO 2020
SYDNEY At the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, Noxopharm, a clinical-stage Australian oncology drug development company, has reported two sets of clinical...
View ArticleClik here to view.
Genetron Health Receives FDA Emergency Use Authorization for SARS-CoV-2 RNA...
BEIJING Genetron Holdings Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, announced that its independently developed detection kit for the...
View Article